This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Meering, P.G. Articles by van Peperzeel, H.A. Search for Related Content PubMed Articles by Meering, P.G. Articles by van Peperzeel, H.A. Social Bookmarking                         What's this?

Kinetic Aspects of Misonidazole and its Major Metabolite in Radiotherapy

Centre for Human Toxicology, State University of Utrecht, Vondellaan 14, 3521 GE Utrecht

D. Gonzalez Gonzalez

Department of Radiotherapy, University of Amsterdam, Wilhelmina Gasthuis, Eerste Helmersstraat 104, 1054 EG Amsterdam

R.A.A. Maes

Centre for Human Toxicology, State University of Utrecht, Vondellaan 14, 3521 GE Utrecht

H.A. van Peperzeel

Department of Radiotherapy, State University of Utrecht, Academic Hospital, Catharijnesingel 101, 3511 GV Utrecht, The Netherlands

1 Oral doses of misonidazole between 0.75 and 1.3 g/m² were administered during 3-5 days per week to 21 patients with various malignancies.

2 Mean plasma levels of misonidazole and desmethylmisonidazole at the times of radiotherapy were in the range 20-50 and 2-12 mg/l respectively.

3 Slight accumulation of misonidazole and desmethylmisonidazole in plasma was observed with a dosage interval of 24 h.

4 In patients with anticonvulsant comedication plasma elimination half-lives of misonidazole of 4.1-8.9 h were found.

5 Observed side-effects were nausea and vomiting (9%), exanthema or rashes (14%) and mild peripheral neuropathy (9%).

Human & Experimental Toxicology, Vol. 4, No. 4, 425-434 (1985)
DOI: 10.1177/096032718500400409


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?